Back to News & Events

Long Island Bioscience Hub Selects Third Bioentrepreneur-In-Residence

Entrepreneur Derek Brand Selected to Facilitate New Bioscience Ventures

STONY BROOK, N.Y. – December 14, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Derek Brand as BioEntrepreneur-In-Residence (B-EIR) for the Long Island Bioscience Hub.  The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions.

Mr. Brand most recently served as Vice President of Business Development at Enumeral Biomedical Corp., which licensed a single cell immunology platform out of MIT and is now a publicly traded biotechnology company with a pipeline of novel immunotherapies in oncology.  In addition to Enumeral, Mr. Brand has held both business and scientific roles at multiple early-stage, venture-backed biomedical startup companies; he has also held commercial leadership roles at GE and the New York Academy of Sciences and presently serves on the advisory board of Allovate LLC, a novel allergy immunotherapy company in NYC. He received his MBA from Babson College and his B.A. in biology from Hamilton College.

“I’m excited to take on the role of BioEntrepreneur-in-Residence and looking forward to bringing a diverse array of startup experience to the LIBH community” Mr. Brand stated. “The opportunity to dig in at the earliest stages of innovation with the exceptional scientists at Long Island institutions is a terrific opportunity, and it’s an honor to have been selected.”

“Mr. Brand is an excellent addition to the team of entrepreneurs engaged in the B-EIR initiative” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “We are excited to see the positive impact these entrepreneurs will have as new companies are launched within the Hub.”

Mr. Brand joins an impressive roster of seven B-EIRs that was expanded in November to include Drs. Brian McCarthy and Gian Luca Araldi. Dr. McCarthy has an extensive background as an investment analyst and as the President and CEO of the startup Influmedix while Dr. Araldi has had a distinguished career in drug discovery within the pharmaceutical industry and as the Founder and Principal of US Pharma Services.

LIBH B-EIRs are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation.  B-EIRs will have the support of the LIBH business and technology development staff, along with external industry advisors to develop successful commercialization strategies, and position the company for SBIR/STTR grant opportunities, and Angel and VC investment. The LIBH can also provide opportunities to access development funding to help advance technologies towards commercialization.  Ultimately, the goal is to foster the creation and growth of new ventures that leverage the exceptional scientific and technological advances taking place at LIBH institutions.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2041 [post_author] => 3 [post_date] => 2016-03-11 19:35:25 [post_date_gmt] => 2016-03-11 19:35:25 [post_content] => Taking place on two days over the course of two weeks at the beginning of March, the 2016 Long Island Innovation Boot Camp/Pre-Seed Workshop was held at the Long Island High Technology Incubator. The annual event, co-organized by the CFB and Stony Brook Universities Clean Energy Business Incubator Program (CEBIP), featured eight technologies emerging from the region’s top research institutions. The event rallies community talent and resources to investigate and transform commercially promising technologies into pre-seed stage companies. Dr. Carol Carter, a molecular Genetics and Microbiology Profession at Stony Brook University, participated in the boot camp this year. About her experience in the boot camp, she noted to Innovate Long Island, “It’s given me an education of a type I’ve not gotten before, in all of my training. As an academician, you don’t usually get this kind of perspective on what you do.” Read additional articles on the event here and here. [post_title] => 2016 Long Island Innovation Boot Camp [post_excerpt] => Held at the Long Island High Technology incubator, this annual event, co-organized by the CFB and Stony Brook Universities Clean Energy Business Incubator Program (CEBIP), featured eight technologies emerging from the region’s top research institutions. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => 2016-long-island-innovation-boot-camp [to_ping] => [pinged] => [post_modified] => 2016-03-29 20:30:14 [post_modified_gmt] => 2016-03-29 20:30:14 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2041 [menu_order] => 188 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3373 [post_author] => 3 [post_date] => 2019-09-25 16:43:38 [post_date_gmt] => 2019-09-25 16:43:38 [post_content] => A technology that manipulates microRNAs (miRNAs) developed by Jingfang Ju, PhD, a biochemist and Professor in the Department of Pathology at the Renaissance School of Medicine at Stony Brook University, and colleagues has shown promise when used as anti-cancer therapeutic. The technology has been licensed to Curamir Therapeutics Inc., Research leading to the development of the miRNA drug platform was funded in part by grants from the Long Island Bioscience Hub, led by the Center for Biotechnology at Stony Brook University, under the National Institutes of Health REACH  program, as well as the National Cancer Institute. An incubated company financed by Delos Capital, Curamir will begin developing these drugs for testing with an initial $10 million in financing from Delos Capital. The company was co-founded by Dr. Ju and Dr. James Watson, co-discoverer of the DNA structure; and Dr. Lan Bo Chen, Professor Emeritus of Pathology at Harvard Medical School and Academician of the Academia Sinica of Taiwan. [post_title] => LIBH Supported Technology Licensed to Startup [post_excerpt] => A technology developed by LIBH researcher Dr. Jingfang Ju, has been licensed to Curamir Therapeutics. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => libh-supported-technology-licensed-to-startup [to_ping] => [pinged] => https://centerforbiotechnology.org/who-we-are/long-island-bioscience-hub/ [post_modified] => 2019-09-25 16:43:38 [post_modified_gmt] => 2019-09-25 16:43:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3373 [menu_order] => 83 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 427 [post_author] => 1 [post_date] => 2014-06-05 08:37:24 [post_date_gmt] => 2014-06-05 08:37:24 [post_content] => The Accelerate Long Island (ALI) Seed Fund and the Long Island Emerging Technologies Fund (LIETF) announced initial investments in five Long Island-based biotech and clean energy startups. Four of the five companies each receiving $100,000 are CFB Client companies: Goddard Labs, PolyNova, SynchroPET and Traverse Biosciences. Read the full press release here. [post_title] => $500k in Funding For Biotech Startups Announced [post_excerpt] => The Accelerate Long Island Seed Fund and the Long Island Emerging Technologies Fund) announced initial investments in five Long Island-based biotech and clean energy startups [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => economic-growth-translating-basic-science-into-commercial-opportunities-2 [to_ping] => [pinged] => http://www.accelerateli.org/accelerate-long-island-and-the-long-island-emerging-technologies-fund-announce-500k-in-funding-for-five-biotech-and-clean-energy-startups/ [post_modified] => 2015-01-28 17:08:26 [post_modified_gmt] => 2015-01-28 17:08:26 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=427 [menu_order] => 228 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

2016 Long Island Innovation Boot Camp

More Information

LIBH Supported Technology Licensed to Startup

More Information

$500k in Funding For Biotech Startups Announced

More Information